News
8th February 2012, Geneva, Switzerland. GeNeuro SA announces today the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis.
GeNeuro develops a pioneering approach for the therapy and diagnosis of diseases associated with human endogenous retrovirus expression with a primary focus on Nervous System diseases.